David Hung's Trading History
| NVCRNovoCure | Jun 05, 2026 | Director | Uninformative Buy | ― | $430.77K | |
| NUVBNuvation Bio | Jun 18, 2025 | President & CEO, Director, Ten Percent Owner | Informative Buy | 890.00K | $278.03M | |
| SIOXSio Gene Therapies | Apr 19, 2017 | ― | Informative Buy | 10.00M | $0.00 | |
| MDVNMedivation | Sep 30, 2016 | ― | Uninformative Sell | ― | $133.32M | |
| ACERAcer Therapeutics | Sep 10, 2009 | ― | Informative Sell | 84.44K | $0.00 | |
| ~ARYAARYA Sciences Acquisition | ― | ― | ― | ― | ||
| ESTAEstablishment Labs Holdings | ― | Director | ― | ― |
You May Also Like
David Hung insider profile FAQ
What is the percentage of profitable transactions made by David Hung?
The percentage of profitable transactions made by David Hung is 75%.
What is the average return per transaction made by David Hung?
The average return per transaction made by David Hung is 78.20%.
What stocks does David Hung hold?
David Hung holds: NVCR, MDVN, SIOX, ESTA, ~ARYA, NUVB, ACER stocks.
What was David Hung's most profitable transaction?
David Hung’s most profitable transaction was an Informative Buy of NUVB stock on June 18, 2025. The return on the trade was 210.60%.
What is David Hung's role in NovoCure?
David Hung's role in NovoCure is Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.
TipRanks measures corporate insiders by the stock transactions they report to the SEC. See how TipRanks ranks experts and calculates performance.